A new type of drug that targets a genetic weakness in an untreatable childhood brain cancer could become the first ever treatment designed to target the disease. The prototype treatment could also offer hope for patients with the rare and devastating 'stone man syndrome' -- in which muscles and ligaments turn to bone.